Literature DB >> 7613159

Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5.

R W Egan1, D Athwahl, C C Chou, S Emtage, C H Jehn, T T Kung, P J Mauser, N J Murgolo, M W Bodmer.   

Abstract

Eosinophils infiltrate into the lungs during asthma and may cause the damage associated with pulmonary inflammation. In allergic animal models, antibodies to interleukin (IL)-5 inhibit pulmonary eosinophilia, tissue damage and hyperreactivity. Sch 55700, a humanized antibody against human IL-5, inhibits eosinophilia in these models with an extended biological duration. On the basis of this dosing regimen and the humanized nature of Sch 55700, it is anticipated that the host response leading to tolerance would be minimized.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7613159     DOI: 10.1159/000237014

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  13 in total

Review 1.  Management of pediatric eosinophilic esophagitis: an update.

Authors:  Seema Khan
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

2.  Anti-interleukin 5 strategies as a potential treatment for asthma.

Authors:  A D Singh; C J Sanderson
Journal:  Thorax       Date:  1997-05       Impact factor: 9.139

Review 3.  Biology of the eosinophil.

Authors:  Carine Blanchard; Marc E Rothenberg
Journal:  Adv Immunol       Date:  2009       Impact factor: 3.543

4.  Allergen-induced increases in IL-5 receptor alpha-subunit expression on bone marrow-derived CD34+ cells from asthmatic subjects. A novel marker of progenitor cell commitment towards eosinophilic differentiation.

Authors:  R Sehmi; L J Wood; R Watson; R Foley; Q Hamid; P M O'Byrne; J A Denburg
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

Review 5.  Reslizumab: First Global Approval.

Authors:  Anthony Markham
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

6.  Regulation of the interleukin-5 receptor alpha-subunit on peripheral blood eosinophils from healthy subjects.

Authors:  C Hellman; G Halldén; B Hylander; J Lundahl
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

Review 7.  Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects.

Authors:  Jorge Máspero
Journal:  Ther Adv Respir Dis       Date:  2017-07-06       Impact factor: 4.031

8.  Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma.

Authors:  Garry M Walsh
Journal:  Biologics       Date:  2013-01-09

Review 9.  Reslizumab in the management of poorly controlled asthma: the data so far.

Authors:  Diego Jose Maselli; Maria Ines Velez; Linda Rogers
Journal:  J Asthma Allergy       Date:  2016-08-31

Review 10.  Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives.

Authors:  Alicia Padilla Galo; Marina Labor; Angelica Tiotiu; Ilaria Baiardini; Nicola Scichilone; Fulvio Braido
Journal:  Patient Relat Outcome Meas       Date:  2018-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.